Table 2.
Univariate survival analyses in relation to PFS and OS in NSCLC patients
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI lower | 95% CI upper | P | HR | 95% CI lower | 95% CI upper | P | |
| Gender | ||||||||
| Female | 1 | 1 | ||||||
| Male | 1.294 | 0.972 | 1.724 | 0.077 | 1.397 | 1.048 | 1.863 | 0.023 |
| Age (years) | ||||||||
| <45 | 1 | 1 | ||||||
| 45–65 | 1.261 | 0.732 | 2.172 | 0.403 | 1.551 | 0.900 | 2.647 | 0.114 |
| 65–80 | 1.570 | 0.912 | 2.702 | 0.104 | 2.142 | 1.244 | 3.689 | 0.006 |
| ≥80 | 2.319 | 1.013 | 5.311 | 0.047 | 3.116 | 1.315 | 7.384 | 0.010 |
| Smoking | ||||||||
| Non-smoker | 1 | 1 | ||||||
| Smoker | 1.269 | 0.971 | 1.659 | 0.081 | 1.477 | 1.128 | 1.933 | 0.005 |
| Differentiation | ||||||||
| Well/ Moderate | 1 | 1 | ||||||
| Poor | 1.208 | 0.877 | 1.665 | 0.247 | 1.190 | 0.863 | 1.640 | 0.289 |
| Histology | ||||||||
| AC | 1 | 1 | ||||||
| SCC | 1.043 | 0.793 | 1.373 | 0.761 | 1.200 | 0.911 | 1.579 | 0.194 |
| Others | 0.725 | 0.268 | 1.959 | 0.526 | 0.716 | 0.265 | 1.940 | 0.512 |
| Tumor stage | ||||||||
| I | 1 | 1 | ||||||
| II | 0.937 | 0.598 | 1.470 | 0.778 | 1.039 | 0.662 | 1.631 | 0.868 |
| III | 1.991 | 1.185 | 3.345 | 0.009 | 2.417 | 1.432 | 4.080 | 0.001 |
| IV | 1.236 | 0.802 | 1.907 | 0.337 | 1.265 | 0.820 | 1.952 | 0.287 |
| Node stage | ||||||||
| N0 | 1 | 1 | ||||||
| N1 | 1.855 | 1.052 | 3.268 | 0.033 | 1.996 | 1.132 | 3.521 | 0.017 |
| N2 | 1.472 | 0.942 | 2.298 | 0.089 | 1.496 | 0.958 | 2.337 | 0.077 |
| N3 | 1.882 | 1.159 | 3.055 | 0.011 | 1.682 | 1.036 | 2.730 | 0.035 |
| Metastasis stage | ||||||||
| M0 | 1 | 1 | ||||||
| M1a | 1.558 | 1.045 | 2.321 | 0.029 | 1.470 | 0.987 | 2.190 | 0.058 |
| M1b | 2.166 | 1.511 | 3.106 | <0.001 | 1.937 | 1.351 | 2.755 | <0.001 |
| TNM stage | ||||||||
| III | 1 | |||||||
| IV | 1.913 | 1.354 | 2.702 | <0.001 | 1.749 | 1.239 | 2.470 | 0.001 |
| Neutrophil (cells/ml) | ||||||||
| ≤3.41 × 109 | 1 | 1 | ||||||
| >3.41 × 109 | 1.783 | 1.279 | 2.486 | 0.001 | 1.756 | 1.260 | 2.447 | 0.001 |
| Platelet (cells/ml) | ||||||||
| ≤177.5 × 109 | 1 | 1 | ||||||
| <177.5 × 109 | 1.248 | 0.923 | 1.687 | 0.150 | 1.221 | 0.903 | 1.651 | 0.195 |
| Lymphocyte (cells/ml) | ||||||||
| ≤2.70 × 109 | 1 | 1 | ||||||
| >2.70 × 109 | 1.002 | 0.472 | 2.128 | 0.996 | 0.883 | 0.415 | 1.878 | 0.747 |
| NLR | ||||||||
| ≤2.68 | 1 | 1 | ||||||
| >2.68 | 1.974 | 1.494 | 2.608 | <0.001 | 2.148 | 1.624 | 2.841 | <0.001 |
| PLR | ||||||||
| ≤119.50 | 1 | 1 | ||||||
| >119.50 | 1.573 | 1.175 | 2.105 | 0.002 | 1.568 | 1.171 | 2.099 | 0.003 |
| CRP (mg/L) | ||||||||
| ≤10.4 | 1 | 1 | ||||||
| >10.4 | 2.230 | 1.683 | 2.955 | <0.001 | 2.281 | 1.724 | 3.019 | <0.001 |
AC, adenocarcinoma; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; PLR, platelet to lymphocyte ratio; SCC, squamous carcinoma; TNM, tumor node metastasis.